Designing the next generation of vaccine adjuvants
Vaccine Insights 2026; 5(3), 191–200
10.18609/vac.2026.024
Published: 21 May
Innovator Insight
Derek O’Hagan, Ed Lavelle, Ari Joffe, Jay T Evans
“Novel adjuvants will emerge when they clearly differentiate themselves and show inherent value that others cannot match.”
Charlotte Barker (Commissioning Editor, Vaccine Insights) speaks with Derek O'Hagan (GSK R&D), Ed Lavelle (Trinity College Dublin), Jay T Evans (Inimmune Corporation), and Ari Joffe (NIAID, NIH) about the state of vaccine adjuvant development, including drivers for new adjuvant innovation, advances in mechanistic understanding, and key barriers to clinical translation.
